Results 241 to 250 of about 122,145 (339)

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review. [PDF]

Ther Adv Psychopharmacol
Lee S, Yin L, Teopiz KM, Wong S, Han Le G, Xiao N, Stahl S, Valentino K, Ho R, Zhang MC, Greg Rhee T, McIntyre RS.   +11 more
europepmc   +1 more source

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Mathias Hempfling, Laura J. Clark, Ludi Fan, Helene Sapin   +7 more
wiley   +1 more source

Dietary Strategies and Nutritional Management in Patients Receiving GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual GIP/GLP‐1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, however, remain unclear.
Rayanne Santos de Paulo, Dandara Baia Bonifácio, Matheus Henrique Lana de Carvalho, Josefina Bressan   +3 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols. [PDF]

Cureus
Davila Diaz R, Campos Barrera E, Diaz Fosado LA, Reyes Esparza A, Perez Benitez OA.   +4 more
europepmc   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the bioequivalence of orally administered orforglipron tablets and capsules in participants with obesity or overweight who were otherwise healthy. Materials and Methods This phase 1, multicenter, open‐label, multiple‐dose, dose‐escalation study was conducted in 429 healthy adults.
Xiaosu Ma, Ying Grace Li, Sohini Raha, David C. Sperry, David E. Coutant, Shobha Bhattachar   +5 more
wiley   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices. [PDF]

ESC Heart Fail
Ibrahim R, Nhat H, Abdelnabi M, Forst B, Allam M, Mee XC, Lim GK, Bcharah G, Barry T, Farina J, Ayoub C, Arsanjani R, Lee K.   +12 more
europepmc   +1 more source

The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome. [PDF]

JACC Adv
Kumar S, Anderson JE, Coviello A, Lopez-Jimenez F, Bakris GL.   +4 more
europepmc   +1 more source

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder. [PDF]

J Prim Care Community Health
Meilinger A, Campbell MA, Reynolds HM, Chavez AS.   +3 more
europepmc   +1 more source